AR043059A1 - DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS - Google Patents

DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS

Info

Publication number
AR043059A1
AR043059A1 ARP030104059A ARP030104059A AR043059A1 AR 043059 A1 AR043059 A1 AR 043059A1 AR P030104059 A ARP030104059 A AR P030104059A AR P030104059 A ARP030104059 A AR P030104059A AR 043059 A1 AR043059 A1 AR 043059A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
optionally substituted
phenyl
independently selected
Prior art date
Application number
ARP030104059A
Other languages
Spanish (es)
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AR043059A1 publication Critical patent/AR043059A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuesto para uso en el tratamiento de trastornos hiper-proliferativos y sus composiciones farmacéuticas. Reivindicación 1: Un compuesto de fórmula (1) en el cual Ar representa un anillo aromático de 6 miembros que contiene 0, 1 ó 2 átomos de N; R1 y R2 se seleccionan, cada uno en forma independiente, de H, halo, CF3, C(O)R9, un radical de fórmula (2), alquilo (C1-6) sustituido en forma opcional con hasta dos sustituyentes seleccionados de OH, alcoxi (C1-3), F, y fenilo, alcoxi (C1-6) sustituido en forma opcional con uno ó dos sustituyentes seleccionados, cada uno en forma independiente, de un radical de fórmula (2) y N[(alquilo C1-3)]2 donde cada alquilo se sustituye en forma opcional e independiente hasta dos veces con alcoxi (C1-3); NHalquilo (C1-3) donde dicho alquilo está sustituido en forma opcional con hasta dos sustituyentes seleccionados, cada uno en forma independiente de OH, F, alcoxi (C1-3), N[alquilo (C1-3)]2, NHalquilo (C1-3), fenilo, pirrolidinilo, y un radical de fórmula (2); N[alquilo (C1-3)]2 donde cada alquilo está sustituido en forma opcional e independiente con hasta dos sustituyentes seleccionados, cada uno en forma independiente, de OH, F, fenilo, y alcoxi (C1-3), dicho alcoxi está sustituido en forma opcional con un radical de la fórmula (2); pirrolidinilo sustituido en forma opcional hasta dos veces con N[alquilo (C1-3)]2; fenilo sustituido en forma opcional con hasta dos sustituyentes seleccionados, cada uno en forma independiente, de alquilo (C1-3), alcoxi (C1-3), halo, CF3, y CN, con la salvedad de que cuando Ar contiene 1 ó 2 átomos de N, R1 y R2 deben ser, cada uno H, y R1 y R2 junto con los átomos de C adyacentes a los cuales están unidos forman un anillo seleccionado de benzo, dioxolo y imidazo, dicho imidazo está sustituido en forma opcional hasta dos veces con alquilo (C1-3), con la salvedad de que R1 y R2 junto con los átomos de C adyacentes a los cuales están unidos forman un anillo sólo cuando Ar no contiene átomos de N; R3 se selecciona de H, alquilo (C1-4), OH, NO2, NH2, NHalquilo (C1-4), NHC(O)alquilo (C1-4) y NHC(O)fenilo, dicho fenilo está sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3), alcoxi (C1-3), halo, CF3, y CN; R4 se selecciona de H, OH, halo, CN, C(O)R6, S(O)2R7, OSi[alquilo (C1-4)]3, tetrazolilo, tienilo, pirrolilo, pirimidinilo, oxazolilo, furanilo, alquilo (C1-6), alquenilo (C2-6) ó alquinilo (C2-6), cada uno sustituido en forma opcional con OH, F, OC(O)NHfenilo, NHC(O)alquilo (C1-3), C(O)NH2, C(O)NH alquilo (C1-3), C(O)N[alquilo (C1-3)]2, un radical de la fórmula (2); alcoxi (C1-3) sustituido en forma opcional hasta dos veces con alcoxi (C1-3), NHC(O)NH alquilo (C1-3) donde dicho alquilo está sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de OH, alcoxi (C1-3), F y fenilo; NHC(O)NHfenilo donde dicho fenilo está sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3), alcoxi (C1-3), halo, CF3, CN, y un radical de la fórmula (2); NHC(O)N[(alquilo C1-3)]2 donde cada alquilo se sustituye en forma opcional e independiente hasta dos veces con alcoxi (C1-3), NH-fenilo, dicho fenilo está sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3), alcoxi (C1-3), halo, CN, y un radical de la fórmula (2); N[alquilo (C1-3)]2 donde cada alquilo se sustituye en forma opcional e independiente hasta dos veces con alcoxi (C1-3); fenilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3), alcoxi (C1-3), halo, CN, CF3, y un radical de la fórmula (2); pirrolidinilo sustituido en forma opcional hasta dos veces con N[alquilo (C1-3)]2, alcoxi (C1-6) sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alcoxi (C1-3), pirrolidinilo, un radical de la fórmula (2) y N[alquilo (C1-3)]2 donde cada alquilo está sustituido en forma opcional e independiente con hasta dos sustituyentes seleccionados en forma independiente de OH, F, alcoxi (C1-3) y fenilo; N[alquilo (C1-4)]2 donde cada uno de dichos grupos alquilo están sustituidos en forma independiente y opcional con hasta dos sustituyentes seleccionados en forma independiente de OH, alquilo (C1-3), F, alcoxi (C1-3), y fenilo; oxadiazolilo sustituido en forma opcional hasta dos veces con alquilo (C1-3); fenilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alcoxi (C1-3), CN, alquilo (C1-3), halo, C(O)-radical de la fórmula (2), un radical de la fórmula (2), C(O)-alquilo (C1-3) sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alcoxi (C1-3), OH, alcoxi (C1-3), F, y fenilo; y C(O)N[alquilo (C1-3)]2 donde cada uno de dichos grupos alquilo están sustituidos en forma independiente y opcional hasta dos veces con alcoxi (C1-3); piridilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3); C(O)N[alquilo (C1-3)]2 donde cada uno de dichos grupos alquilo están sustituidos en forma independiente y opcional hasta dos veces con alcoxi (C1-3), y O-piridilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de CF3, halo, y alquilo (C1-3); R5 se selecciona de H, halo, CN, alcoxi (C1-6), y alquilo (C1-6); R6 se selecciona de OH, NHR10, O-cicloalquilo (C3-6), alcoxi (C1-3), O-alquenilo (C2-6), O-alquinilo (C3-6), alquilo (C1-6) sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de OH, alcoxi (C1-3), F, y fenilo; N[alquilo (C1-4)]2 donde cada uno de dichos grupos alquilo están sustituidos en forma independiente y opcional con hasta dos sustituyentes seleccionados en forma independiente de OH, CN, N[alquilo (C1-4)]2, alcoxi (C1-3), S(O)2-fenilo, S(O)2-alquilo (C1-3), fenilo, furilo, tetrahidrofurilo, cicloalquilo (C3-6), y piridilo; N[alquilo (C1-3)]R8 en donde el [alquilo (C1-3)] está sustituido en forma opcional hasta dos veces con alcoxi (C1-3), N[cicloalquilo (C3-6)]alquilo (C1-3) donde dicho alquilo está sustituido con hasta dos sustituyentes seleccionados en forma independiente de alcoxi (C1-3), OH, CN; N[alquilo (C1-4)]2, S(O)2-fenilo, S(O)2-alquilo (C1-3), fenilo, furilo, tetrahidrofurilo, cicloalquilo (C5-C6), y piridilo; pirrolidinilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de NH2, NHalquilo (C1-3), N[alquilo (C1-4)]2, C(O)NH2, NHC(O)alquilo (C1-3), NHS(O)2-alquilo (C1-3), piridilo, N[alquilo (C1-3)]C(O)NHalquilo (C1-3), N[alquilo (C1-3)]C(O)alquilo (C1-3), y alquilo (C1-3) sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de N[alquilo (C1-4)]2, alcoxi (C1-3), y pirrolidinilo; morfolinilo sustituido en forma opcional hasta dos veces con alquilo (C1-3); tiomorfolinilo sustituido en forma opcional hasta dos veces con alquilo (C1-3); piperazinilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de pirazinilo, C(O)NH2, C(O)NH-fenilo, C(O)-furanilo, C(O) alquilo (C1-3), C(O)NHalquilo (C1-3), C(O)N[alquilo (C1-3)]R8, S(O)2-alquilo (C1-3), S(O)2-fenilo, un radical de la fórmula (2), piridilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3), CN y CF3, fenilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3), CN, halo, CF3, y alcoxi (C1-3), alquilo (C1-3) sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de OH, F, fenilo, alcoxi (C1-3), N[alquilo (C1-3)]2, pirrolidinilo, C(O)-pirrolidinilo, C(O)-radical de la fórmula (2), un radical de la fórmula (2), y piridilo sustituido en forma opcional hasta dos veces con alcoxi (C1-3), y piperidinilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de fenilo, piridilo, pirrolidinilo y oxo-dihidrobencimidazolilo; R7 se selecciona de NH2, pirrolidinilo, un radical de la fórmula (2), NHalquilo (C1-3) dicho alquilo está sustituido en forma opcional con hasta dos veces con alcoxi (C1-3), NH-fenilo dicho fenilo está sustituido en forma opcional con hasta dos sustituyentes seleccionados independientemente de alquilo (C1-3), CN, alcoxi (C1-4), halo y CF3, N[alquilo (C1-3)]2 donde cada alquilo se sustituye en forma opcional e independiente hasta dos veces con alcoxi (C1-4), y fenilo sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alquilo (C1-3), alcoxi (C1-3), halo, CF3 y CN; R8 se selecciona de alcoxi (C1-3), piridilo, piperidinilo, piranilo y fenilo, donde cada resto de anillo está sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de alcoxi (C1-3), y alquilo (C1-3); R9 se selecciona de alquilo (C1-3), alcoxi (C1-3), OH, un radical de la fórmula (2), fenilo sustituido en forma opcional con alquilo (C1-3), alcoxi (C1-3), halo, CF3, y CN, N[alquilo (C1-4)]2 donde cada uno de dichos grupos alquilo están sustituidos en forma independiente y opcional con OH, CN, N[alquilo (C1-4)]2, alcoxi (C1-4), S(O)2-fenilo, S(O)2-alquilo (C1-3), fenilo, furilo, tetrahidrofurilo, cicloalquilo (C3-6), y piridilo, y pirrolidinilo sustituido en forma opcional con N[alquilo (C1-3)]2; y, sólo cuando Ar no contiene átomos de N, R9 también se selecciona de piridilo, tienilo, y NHR10; R10 se selecciona de H, indolilo, alquilo (C1-4) sustituido en forma opcional con hasta dos sustituyentes seleccionados en forma independiente de OH, F, fenilo, alcoxi (C1-4), NHC(O)alquilo (C1-3), S-(alquilo C1-3), bencimidazolilo, indolilo, tienilo, pirazolilo, un radical de la fórmula (2), N[alquilo (C1-4)]2 donde cada alquilo está sustituido en forma opcional e independieCompound for use in the treatment of hyper-proliferative disorders and their pharmaceutical compositions. Claim 1: A compound of formula (1) in which Ar represents a 6-membered aromatic ring containing 0, 1 or 2 N atoms; R1 and R2 are each independently selected from H, halo, CF3, C (O) R9, a radical of formula (2), (C1-6) alkyl optionally substituted with up to two substituents selected from OH , (C1-3) alkoxy, F, and phenyl, (C1-6) alkoxy optionally substituted with one or two substituents selected, each independently, from a radical of formula (2) and N [(C1 alkyl -3)] 2 where each alkyl is optionally and independently substituted up to twice with (C1-3) alkoxy; NH (C1-3) alkyl where said alkyl is optionally substituted with up to two selected substituents, each independently of OH, F, (C1-3) alkoxy, N [(C1-3) alkyl] 2, NHalkyl ( C1-3), phenyl, pyrrolidinyl, and a radical of formula (2); N [(C1-3) alkyl] 2 where each alkyl is optionally and independently substituted with up to two substituents selected, each independently, from OH, F, phenyl, and (C1-3) alkoxy, said alkoxy is optionally substituted with a radical of the formula (2); pyrrolidinyl optionally substituted up to twice with N [(C1-3) alkyl] 2; phenyl optionally substituted with up to two substituents selected, each independently, of (C1-3) alkyl, (C1-3) alkoxy, halo, CF3, and CN, with the proviso that when Ar contains 1 or 2 atoms of N, R1 and R2 must each be H, and R1 and R2 together with the adjacent C atoms to which they are attached form a ring selected from benzo, dioxolo and imidazo, said imidazo is optionally substituted up to two times with (C1-3) alkyl, with the proviso that R1 and R2 together with the adjacent C atoms to which they are attached form a ring only when Ar does not contain N atoms; R3 is selected from H, (C1-4) alkyl, OH, NO2, NH2, NHalkyl (C1-4), NHC (O) alkyl (C1-4) and NHC (O) phenyl, said phenyl is optionally substituted with up to two substituents independently selected from (C1-3) alkyl, (C1-3) alkoxy, halo, CF3, and CN; R4 is selected from H, OH, halo, CN, C (O) R6, S (O) 2R7, OSi [(C1-4) alkyl] 3, tetrazolyl, thienyl, pyrrolyl, pyrimidinyl, oxazolyl, furanyl, (C1 -6), (C2-6) alkenyl or (C2-6) alkynyl, each optionally substituted with OH, F, OC (O) NHphenyl, NHC (O) (C1-3) alkyl, C (O) NH2, C (O) NH (C1-3) alkyl, C (O) N [(C1-3) alkyl] 2, a radical of the formula (2); (C1-3) alkoxy optionally substituted up to twice with (C1-3) alkoxy, NHC (O) NH (C1-3) alkyl where said alkyl is optionally substituted with up to two substituents independently selected from OH , (C1-3) alkoxy, F and phenyl; NHC (O) NHphenyl wherein said phenyl is optionally substituted with up to two substituents independently selected from (C1-3) alkyl, (C1-3) alkoxy, halo, CF3, CN, and a radical of the formula (2 ); NHC (O) N [(C1-3 alkyl)] 2 where each alkyl is optionally and independently substituted up to twice with (C1-3) alkoxy, NH-phenyl, said phenyl is optionally substituted with up to two substituents independently selected from (C1-3) alkyl, (C1-3) alkoxy, halo, CN, and a radical of the formula (2); N [(C1-3) alkyl] 2 where each alkyl is optionally and independently substituted up to twice with (C1-3) alkoxy; phenyl optionally substituted with up to two substituents independently selected from (C1-3) alkyl, (C1-3) alkoxy, halo, CN, CF3, and a radical of the formula (2); pyrrolidinyl optionally substituted up to twice with N [(C1-3) alkyl] 2, (C1-6) alkoxy optionally substituted with up to two substituents independently selected from (C1-3) alkoxy, pyrrolidinyl, a radical of the formula (2) and N [(C1-3) alkyl] 2 where each alkyl is optionally and independently substituted with up to two substituents independently selected from OH, F, (C1-3) alkoxy and phenyl; N [(C1-4) alkyl] 2 where each of said alkyl groups are independently and optionally substituted with up to two substituents independently selected from OH, (C1-3) alkyl, F, (C1-3) alkoxy , and phenyl; oxadiazolyl optionally substituted up to twice with (C1-3) alkyl; optionally substituted phenyl with up to two substituents independently selected from (C1-3) alkoxy, CN, (C1-3) alkyl, halo, C (O) -radical of the formula (2), a radical of the formula (2), C (O) -C1-3alkyl optionally substituted with up to two substituents independently selected from (C1-3) alkoxy, OH, (C1-3) alkoxy, F, and phenyl; and C (O) N [(C1-3) alkyl] 2 where each of said alkyl groups are independently and optionally substituted up to twice with (C1-3) alkoxy; pyridyl optionally substituted with up to two substituents independently selected from (C1-3) alkyl; C (O) N [(C1-3) alkyl] 2 where each of said alkyl groups are independently and optionally substituted up to twice with (C1-3) alkoxy, and O-pyridyl optionally substituted with up to two substituents independently selected from CF3, halo, and (C1-3) alkyl; R5 is selected from H, halo, CN, (C1-6) alkoxy, and (C1-6) alkyl; R6 is selected from OH, NHR10, O-cycloalkyl (C3-6), alkoxy (C1-3), O-alkenyl (C2-6), O-alkynyl (C3-6), alkyl (C1-6) substituted in optionally with up to two substituents independently selected from OH, (C1-3) alkoxy, F, and phenyl; N [(C1-4) alkyl] 2 where each of said alkyl groups are independently and optionally substituted with up to two substituents independently selected from OH, CN, N [(C1-4) alkyl] 2, alkoxy ( C1-3), S (O) 2-phenyl, S (O) 2-C1-3 alkyl, phenyl, furyl, tetrahydrofuryl, (C3-6) cycloalkyl, and pyridyl; N [(C1-3) alkyl] R8 wherein [C1-3] alkyl is optionally substituted up to twice with (C1-3) alkoxy, N [C3-6) cycloalkyl] (C1-) alkyl 3) wherein said alkyl is substituted with up to two substituents independently selected from (C1-3) alkoxy, OH, CN; N [(C1-4) alkyl] 2, S (O) 2-phenyl, S (O) 2-C1-3 alkyl, phenyl, furyl, tetrahydrofuryl, (C5-C6) cycloalkyl, and pyridyl; pyrrolidinyl optionally substituted with up to two substituents independently selected from NH2, NH (C1-3) alkyl, N [(C1-4) alkyl] 2, C (O) NH2, NHC (O) (C1-3) alkyl , NHS (O) 2-C1-3 alkyl, pyridyl, N [C1-3 alkyl] C (O) NH3-3 alkyl, N [C1-3 alkyl] C (O) alkyl (C1-3), and (C1-3) alkyl optionally substituted with up to two substituents independently selected from N [(C1-4) alkyl] 2, (C1-3) alkoxy, and pyrrolidinyl; optionally substituted morpholinyl up to twice with (C1-3) alkyl; thiomorpholinyl optionally substituted up to twice with (C1-3) alkyl; piperazinyl optionally substituted with up to two substituents independently selected from pyrazinyl, C (O) NH2, C (O) NH-phenyl, C (O) -furanyl, C (O) (C1-3) alkyl, C ( O) NH (C1-3) alkyl, C (O) N [(C1-3) alkyl] R8, S (O) 2-C1-3 alkyl, S (O) 2-phenyl, a radical of the formula (2), pyridyl optionally substituted with up to two substituents independently selected from (C1-3) alkyl, CN and CF3, phenyl optionally substituted with up to two substituents independently selected from (C1-3) alkyl, CN, halo, CF3, and (C1-3) alkoxy, (C1-3) alkyl optionally substituted with up to two substituents independently selected from OH, F, phenyl, (C1-3) alkoxy, N [alkyl ( C1-3)] 2, pyrrolidinyl, C (O) -pyrrolidinyl, C (O) -radical of the formula (2), a radical of the formula (2), and pyridyl optionally substituted up to twice with alkoxy ( C1-3), and piperidinyl optionally substituted with up to two substituents selected s independently of phenyl, pyridyl, pyrrolidinyl and oxo-dihydrobenzimidazolyl; R7 is selected from NH2, pyrrolidinyl, a radical of the formula (2), NHalkyl (C1-3) said alkyl is optionally substituted with up to twice with (C1-3) alkoxy, NH-phenyl said phenyl is substituted by optionally with up to two substituents independently selected from (C1-3) alkyl, CN, (C1-4) alkoxy, halo and CF3, N [(C1-3) alkyl] 2 where each alkyl is optionally and independently substituted up to twice with (C1-4) alkoxy, and phenyl optionally substituted with up to two substituents independently selected from (C1-3) alkyl, (C1-3) alkoxy, halo, CF3 and CN; R8 is selected from (C1-3) alkoxy, pyridyl, piperidinyl, pyranyl and phenyl, where each ring moiety is optionally substituted with up to two substituents independently selected from (C1-3) alkoxy, and (C1-) alkyl 3); R9 is selected from (C1-3) alkyl, (C1-3) alkoxy, OH, a radical of the formula (2), phenyl optionally substituted with (C1-3) alkyl, (C1-3) alkoxy, halo , CF3, and CN, N [(C1-4) alkyl] 2 where each of said alkyl groups are independently and optionally substituted with OH, CN, N [(C1-4) alkyl] 2, (C1-) alkoxy 4), S (O) 2-phenyl, S (O) 2-C1-3 alkyl, phenyl, furyl, tetrahydrofuryl, C3-6 cycloalkyl, and pyridyl, and pyrrolidinyl optionally substituted with N [alkyl (C1-3)] 2; and, only when Ar does not contain N atoms, R9 is also selected from pyridyl, thienyl, and NHR10; R10 is selected from H, indolyl, (C1-4) alkyl optionally substituted with up to two substituents independently selected from OH, F, phenyl, (C1-4) alkoxy, NHC (O) (C1-3) alkyl , S- (C1-3 alkyl), benzimidazolyl, indolyl, thienyl, pyrazolyl, a radical of the formula (2), N [C1-4 alkyl] 2 where each alkyl is optionally and independently substituted

ARP030104059A 2002-11-12 2003-11-05 DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS AR043059A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42549002P 2002-11-12 2002-11-12
US46091503P 2003-04-07 2003-04-07
US48420203P 2003-06-30 2003-06-30

Publications (1)

Publication Number Publication Date
AR043059A1 true AR043059A1 (en) 2005-07-13

Family

ID=32314888

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104059A AR043059A1 (en) 2002-11-12 2003-11-05 DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS

Country Status (17)

Country Link
EP (1) EP1565455A1 (en)
JP (1) JP2006509840A (en)
KR (1) KR20050072824A (en)
AR (1) AR043059A1 (en)
AU (1) AU2003290744A1 (en)
BR (1) BR0316169A (en)
CA (1) CA2505819A1 (en)
EC (1) ECSP055851A (en)
HR (1) HRP20050496A2 (en)
MA (1) MA27557A1 (en)
MX (1) MXPA05004779A (en)
NO (1) NO20052796L (en)
PE (1) PE20040832A1 (en)
PL (1) PL376867A1 (en)
TW (1) TW200418834A (en)
UY (1) UY28074A1 (en)
WO (1) WO2004043950A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005054201A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CA2546002C (en) 2003-11-20 2012-09-18 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2005051957A1 (en) * 2003-11-21 2005-06-09 Bayer Pharmaceuticals Corporation Indolyl-thieno`3,4-b!pyrazin-3-one derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
UA93351C2 (en) 2004-06-30 2011-02-10 Янссен Фармацевтика Н.В. Phthalazine derivatives as parp inhibitors
ES2415771T3 (en) 2004-06-30 2013-07-26 Janssen Pharmaceutica N.V. Quinazoline derivatives as PARP inhibitors
NZ551840A (en) 2004-06-30 2009-07-31 Janssen Pharmaceutica Nv Substituted 2-alkyl quinzolinone derivatives as PARP inhibitors
BRPI0517734A (en) 2004-11-17 2008-10-21 Korea Res Inst Chem Tech 1 - [(6,7-substituted alkoxyquinoxalinyl) aminocarbonyl] -4- (hetero) arylpiperazine derivatives
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TWI337182B (en) 2005-05-12 2011-02-11 Abbott Lab Apoptosis promoters
WO2008016123A1 (en) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
EP2134691B1 (en) 2007-03-08 2012-01-25 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp and tank inhibitors
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
CA2741537A1 (en) * 2008-11-07 2010-05-14 Wyeth Llc Quinoxaline-based lxr modulators
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
SI3122358T1 (en) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
CN106456648B (en) 2014-03-26 2021-11-02 阿斯特克斯治疗有限公司 Combination of FGFR inhibitor and IGF1R inhibitor
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
CA2974078A1 (en) 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP6896711B2 (en) 2015-09-23 2021-06-30 ヤンセン ファーマシューティカ エヌ．ベー． Biheteroaryl substitutions 1,4-benzodiazepines and their use for the treatment of cancer
SI3353177T1 (en) 2015-09-23 2020-08-31 Janssen Pharmaceutica Nv Tricyclic heterocycles for the treatment of cancer
AU2022354321A1 (en) * 2021-09-29 2024-04-04 Repare Therapeutics Inc. N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta
WO2024069592A1 (en) * 2022-09-29 2024-04-04 Repare Therapeutics Inc. N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Also Published As

Publication number Publication date
ECSP055851A (en) 2005-09-20
UY28074A1 (en) 2004-05-31
WO2004043950A1 (en) 2004-05-27
PL376867A1 (en) 2006-01-09
EP1565455A1 (en) 2005-08-24
AU2003290744A1 (en) 2004-06-03
JP2006509840A (en) 2006-03-23
NO20052796D0 (en) 2005-06-09
MXPA05004779A (en) 2005-07-22
HRP20050496A2 (en) 2006-06-30
BR0316169A (en) 2005-09-27
NO20052796L (en) 2005-06-09
TW200418834A (en) 2004-10-01
PE20040832A1 (en) 2005-01-27
KR20050072824A (en) 2005-07-12
MA27557A1 (en) 2005-10-03
CA2505819A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
AR043059A1 (en) DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
NO20063355L (en) Novel tricyclic spiro derivatives as modulators of chemokine receptor activity
CO5670358A2 (en) DERIVATIVES OF 2-PIRIDONE AS INHIBITORS OF ELASTASA NEUTROFILA AND ITS USE
AR057934A2 (en) COMPOSITES OF PIRAZOLOPIRIMIDINONES PHOSPHODIESTERASE INHIBITORS TYPE 5 GMPC PDE5
CO5580768A2 (en) DERIVATIVES OF 4,5-DIARILTIAZOL AS LIGANDOS CB-1
AR040230A1 (en) INDOL, AZAINDOL, AND RELATED HETEROCICLES OF 4-ALQUENIL PIPERIDINA
NO20064309L (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators for dopamine D3 receptors
AR044614A1 (en) SULFONAMIDE COMPOSITIONS THAT MODULATE THE ACTIVITY OF THE KINIOQUIN RECEIVER (CCR4)
AR057131A1 (en) PURINE DERIVATIVES AS IMMUNOMODULATOR
CY1112084T1 (en) 5-phenylthiazole derivative and its use as kinase inhibitors PI3
CY1116885T1 (en) Substituted cyclohexylmethyl derivatives
UY29703A1 (en) "MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS"
AR049418A1 (en) DERIVATIVES OF HETEROARILAMINOPIRAZOL AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES.
DE602006018152D1 (en) TRIAZONE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
AR111850A1 (en) SUBSTITUTED TRIFLUOROMETILOXADIAZOLS TO FIGHT FITOPATHOGEN FUNGI
AR049346A1 (en) 3-AMINO-1-ARILPROPIL-INDOLES AS MONOAMINE REABSORTION INHIBITORS
PE20070212A1 (en) 1,4-DIHYDROPYRIDINE-CONDENSED HETEROCYCLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM
MX339668B (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor.
AR074486A1 (en) DERIVATIVES OF QUINOLONA USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES, IN PARTICULAR PARKINSON, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND PROCESS TO PREPARE THEM.
AR058319A1 (en) N- (FLUOROPIRAZINIL) PHENYLSULPHONAMIDS AS MODULATORS OF THE CHRIOCHINES CCR4 RECEIVER
HRP20090050T3 (en) Novel pyrrolidine-3,4-dicarboxamide derivatives
AR041864A1 (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
AR041689A1 (en) PIRIDOINDOLONA DERIVATIVES SUBSTITUTED IN 3- BY A PHENYLL ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
ES2177275T3 (en) DERIVATIVES OF OXADIAZOLINE AND ITS USE AS INSECTICIDES.
AR034700A1 (en) PIRIMIDINE DERIVATIVES, PROCESSES TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THE USE OF SUCH COMPOUNDS FOR THE DEVELOPMENT OF MEDICINES

Legal Events

Date Code Title Description
FB Suspension of granting procedure